EG-70 (phase 1) + EG-70 (phase 2)
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Superficial Bladder Cancer
Conditions
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Trial Timeline
Apr 22, 2021 → Nov 30, 2028
NCT ID
NCT04752722About EG-70 (phase 1) + EG-70 (phase 2)
EG-70 (phase 1) + EG-70 (phase 2) is a phase 1/2 stage product being developed by enGene for Superficial Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04752722. Target conditions include Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04752722 | Phase 1/2 | Recruiting |
Competing Products
11 competing products in Superficial Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gemcitabine | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + mitomycin C | Eli Lilly | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Diclofenac gel | Novartis | Approved | 85 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 52 |
| Dalteparin sodium injection | Pfizer | Approved | 84 |
| Rivaroxaban + Fondaparinux | Bayer | Phase 3 | 74 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| Chemophase | Halozyme Therapeutics | Phase 1 | 30 |
| NDV-01 (sustained-release gemcitabine-docetaxel) | Relmada Therapeutics | Phase 3 | 69 |
| EscharEx 5% (EX-02 formulation) | MediWound | Phase 1/2 | 33 |